Core Viewpoint - Duori Pharmaceutical (301075.SZ) is primarily focused on collaborative research and development of innovative drugs, with promising market prospects for its drug candidate Yilung Jisheng Granules, which has completed Phase II clinical trial enrollment as of the end of December 2024 [1] Summary by Relevant Categories Company Development - The company has reported that the Yilung Jisheng Granules have made steady progress in research and development [1] - The specific timeline for the drug's market launch remains uncertain, and the company will fulfill its information disclosure obligations in accordance with relevant regulations [1] Industry Outlook - The market potential for Yilung Jisheng Granules is considered broad, indicating a positive outlook for the company's innovative drug pipeline [1]
多瑞医药(301075.SZ)：公司益肺济生颗粒的研发进展顺利，具体的上市时间具有不确定性